Evidence map›Paper›PMID 42764884›Full record

ReviewActa pharmaceutica Sinica. B2026

Nanomaterial-mediated functional remodeling of antigen-presenting cells: A novel strategy to break tumor immune escape.

Hongzhi Dong, Xueyi Song, Yao Li, Qian Wei, Mingyi Ju, Yunong Li, Qi Cui, Jia Bi, Minjie Wei, Heran Li and 1 more

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongzhi DongDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Xueyi SongDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yao LiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Qian WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Mingyi JuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yunong LiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Qi CuiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Jia BiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Heran LiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Lin ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the cross-integration of nanotechnology and immunology, nanomaterials have shown great potential in tumor treatment. This review begins with the nanomaterials have unique advantages in reshaping the tumor immune microenvironment (TIME), including improving targeting, enhancing stability, increasing delivery efficiency, achieving controllable release, and endowing a multi-functional integrated platform. We then systematically reviews the recently research progress on the multi-mechanism regulation of antigen-presenting cells (APCs) by nanomaterials: (1) In the aspect of dendritic cell activation, we focus on the breakthrough achievements such as the activation of immune responses through the generation of immune signal complexes and the promotion of tumor neoantigen presentation; (2) In the field of macrophage reprogramming, we analyze the applications of nanomaterials in inducing macrophage polarization, improving the anti-tumor phagocytosis of macrophages, blocking macrophage autophagy, and enhancing the synergy of immune cells; (3) In the regulation of B cells, we explore the mechanism by which nanomaterials enhance the germinal center response and thereby exert anti-tumor immune effects. This article further discusses key challenges in clinical translation, including the dynamic fate of nanomaterials in complex TIME and the balance between immunogenicity and efficacy, and proposes future directions for accelerating clinical translation through computer-aided design (such as AI prediction of nanomaterial-immune cell interaction networks) and organ-on-a-chip evaluation systems. This review provides a theoretical framework and technical route for the development of next-generation tumor immunonanomedicines.

Indexed as

Antigen-presenting cellsClinical translationDendritic cellsImmune regulationMacrophage reprogrammingNanomaterialsTumor immune microenvironmentTumor immunotherapy

Identifiers

PMID42764884
PMCPMC13589944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.